MK-2206
- Generic Name
- MK-2206
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H21N5O
- CAS Number
- 1032349-93-1
- Unique Ingredient Identifier
- 51HZG6MP1K
- Associated Conditions
- -
- Associated Therapies
- -
MK-2206 in Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 12
- Registration Number
- NCT01370070
- Locations
- ππ°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 647
- Registration Number
- NCT01306045
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01295632
MK-2206 for Recurrent Malignant Glioma
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT01249105
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈMemorial Sloan Kettering, New York, New York, United States
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 334
- Registration Number
- NCT01248247
- Locations
- πΊπΈ
Yale Universtiy, New Haven, Connecticut, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01243762
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240941
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 17
- Registration Number
- NCT01235897
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01186705
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01169649
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.